Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865228 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT00865228 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 224 participants.
The verdict
NCT00865228, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
Interventions
- DRUG Placebo
- DRUG Lapaquistat acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865228
The ClinicalTrials.gov registry entry for NCT00865228 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00865228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865228 about?
NCT00865228 is a clinical study titled "Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia". The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
What is the current status of trial NCT00865228?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2007-07. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00865228?
The interventions under investigation include: Placebo (DRUG), Lapaquistat acetate (DRUG).
Who is sponsoring clinical trial NCT00865228?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.